News
LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The anti-inflammatory drugs market size has grown rapidly in recent years. From $136.86 billion in 2024, it is predicted to ...
Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...
Global Sepsis Treatment Market Report: Growth, Expansion, and Strategic Insights (2025–2033) The Global Sepsis Treat ...
Of course, some of the rally’s nothing more than the left-behind stocks playing catch up. The drug stocks had a rare day in ...
Bristol-Myers Squibb announced promising progress on its Phase 2 Alzheimer’s clinical trial of BMS-986446, an experimental ...
At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...
During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...
Bristol-Myers Squibb terminated a real-world, non-interventional study on Ozanimod, targeting moderate-to-severe ulcerative ...
Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
2don MSN
While current methods of isolating islet cells for transplantation strip away the structural scaffold that supports the cells ...
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results